Avanos stock stays tied to medical devices.
Avanos Medical Inc (ISIN US05350V1061) is a Nasdaq-listed medical device company specializing in chronic care, pain management, and digestive health products. The company's business model relies on its portfolio of infection prevention, chronic care, and interventional products, which are used in hospital and home-care settings. The article emphasizes the importance of the company's operating mix and product categories, such as enteral feeding, for its growth in the healthcare market.
Avanos, American Industrial Get Regulatory Approval for Merger
Avanos and American Industrial have received regulatory approval for their merger. This development marks a significant step forward for the two companies as they proceed with their integration plans.
Avanos receives regulatory approvals, merger expected to close by July 27 pending shareholder vote
Avanos (AVNS) has secured all necessary regulatory approvals for its acquisition by affiliates of American Industrial Partners. The merger is anticipated to finalize by July 27, 2026, contingent on shareholder approval. A special stockholder meeting for Avanos to vote on the merger is scheduled for July 22, 2026.
Avanos Medical, American Industrial Partners Clear Regulatory Hurdle for Merger
Avanos Medical Inc. and American Industrial Partners (AIP) have received all necessary regulatory approvals for AIP's acquisition of Avanos Medical, moving the deal closer to its projected completion later this month. The merger, valued at approximately $2.2 billion, is now subject to Avanos shareholder approval and other customary closing conditions, with a shareholder vote scheduled for July 22. This regulatory clearance removes a significant hurdle, positioning Avanos for its next phase under AIP's private ownership, focused on innovation and growth in medical technology.
Avanos Medical stock holds its focus on procedure demand
Avanos Medical (AVNS) focuses on procedure demand within its US medtech footprint, with its stock performance tied to hospital and outpatient spending trends. The company, which trades on the NYSE, specializes in products for pain management, digestive health, and respiratory care. Investors are looking for new catalysts beyond operational execution and broader medtech sentiment, as the company's business relies heavily on procedure volumes and healthcare purchasing discipline.
Is Avanos Medical (AVNS) Undervalued Or Has Its Strong Run Already Priced In?
Avanos Medical (AVNS) has seen significant stock performance despite recent net losses and declining longer-term returns. The company's current Price-to-Sales (P/S) multiple of 1.6x is below industry and peer averages, suggesting a discount, but is above an estimated fair P/S ratio of 1.1x. This creates conflicting signals regarding its valuation, prompting investors to consider underlying risks.
Price to sales forward of Avanos Medical, Inc. – LS:A2JNRG
This article displays the forward price-to-sales ratio for Avanos Medical, Inc. (LS:A2JNRG) on TradingView. It indicates that the market was closed at the time of viewing, with no trades having occurred. The page provides an overview of financial data for the company.
Is Avanos Medical (AVNS) Undervalued Or Has Its Strong Run Already Priced In?
Avanos Medical (AVNS) has seen strong stock performance over the last three months and year-to-date, contrasting with longer-term declines and a recent net loss of $74.4 million. The company's current Price-to-Sales (P/S) ratio of 1.6x is below its industry average but above an estimated fair P/S of 1.1x, leading to mixed valuation signals. Investors are advised to consider the key risks and warning signs before making investment decisions.
Avanos Medical with steady outlook, shares tracked against medtech peers
Avanos Medical is focused on single-use medical devices and is situated within a consolidating medtech sector, with its shares tracked against competitors like Medtronic and Boston Scientific. Analysts generally hold a moderate upside view on AVNS shares, focusing on the company's margin profile and profitability expansion efforts. The company generates revenue from recurring sales of disposable medical products used in high-frequency procedures, with quarterly earnings reports providing key insights into its financial performance.
Avanos Medical, Inc.(NYSE: AVNS) dropped from Russell 2000 Defensive Index
Avanos Medical, Inc. (NYSE: AVNS) has been removed from the Russell 2000 Defensive Index. This news follows several recent updates for the company, including first-quarter earnings results and an announcement of its acquisition by American Industrial Partners for $1.27 billion. Avanos Medical specializes in medical device solutions, including specialty nutrition systems and pain management products.
Avanos Medical, Inc. Actuals & Estimates (NYSE:AVNS)
This article provides an overview of Avanos Medical, Inc. (NYSE:AVNS) stock's financial performance, including actuals and estimates for income, balance sheet, and cash flow. It details current stock price, historical highs and lows, market capitalization, and upcoming earnings report dates. The article also touches on volatility, dividend policy, employee count, EBITDA, and analyst ratings.
AVNS - Avanos Medical Inc Latest SEC Filings
This article provides detailed financial data and market performance metrics for Avanos Medical Inc (AVNS), including its stock price, market capitalization, income, sales, and various financial ratios. It also lists key dates, such as IPO and earnings, along with insider and institutional ownership statistics, and short interest data.
Price to earnings forward of Avanos Medical, Inc. – BOATS:AVNS
This article provides the "Price to earnings forward" metric for Avanos Medical, Inc. (AVNS) on the Blue Ocean Alternative Trade System (BOATS) platform. It indicates that the market is closed, with no trades currently available for the stock. The content is primarily a listing of financial data and information services provided by TradingView and its partners.
Price-Driven Insight from (AVNS) for Rule-Based Strategy
This article provides a price-driven insight into Avanos Medical Inc. (AVNS) for rule-based trading strategies. It highlights neutral near and mid-term readings but a strong long-term positive bias, noting that resistance is being tested. The analysis details institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and risk-reward ratios.
Avanos Medical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avanos Medical, Inc. - AVNS
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Avanos Medical, Inc. (NYSE: AVNS) to affiliates of American Industrial Partners. KSF is scrutinizing the $25.00 per share cash offer to determine if it adequately values the company and if the sales process was fair. Shareholders who believe the transaction undervalues Avanos Medical are encouraged to contact KSF to discuss their legal rights.
Reasons to Retain Avanos Medical Stock in Your Portfolio for Now
Avanos Medical (AVNS) is well-positioned for growth due to its strong product line, particularly in Specialty Nutrition Systems, and strategic acquisitions like Nexus Medical, despite challenges from tariff risks and weaknesses in its Pain Management & Recovery business. The company is actively optimizing its portfolio, divesting underperforming assets, and expanding globally to mitigate tariff exposure and achieve long-term revenue targets. While facing near-term profitability pressures, its strategic moves and strong earnings yield suggest a favorable outlook, indicating it's a stock to retain.
Reasons to Retain Avanos Medical Stock in Your Portfolio for Now
Avanos Medical (AVNS) is positioned for growth due to strong performance in its Specialty Nutrition Systems segment, strategic portfolio optimization, and an upcoming acquisition by American Industrial Partners. However, the company faces headwinds from persistent tariff and margin pressures, weaknesses in its Pain Management & Recovery segment, and execution risks associated with its portfolio restructuring. Despite these challenges, its Specialty Nutrition Systems segment continues to deliver robust growth, while ongoing strategic adjustments aim to enhance long-term profitability.
Avanos Medical Inc (AVNS) Institutional Confidence
Avanos Medical Inc (AVNS) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. This score reflects a 97.19% institutional shareholding proportion, although this represents a 14.66% decrease quarter-over-quarter. Diamond Hill Capital is the largest institutional shareholder, holding 1.23% of outstanding shares.
Avanos Medical Stock - Long-term strategy in focus for medtech specialist
Avanos Medical focuses on single-use medical devices for pain management and minimally invasive care. The article highlights the company's long-term strategy, portfolio mix, and market positioning against larger medtech competitors. It also discusses Avanos's revenue drivers, capital allocation, competitive landscape, regulatory considerations, and operational footprint, emphasizing its specialization in chronic care and pain management.
Avanos Medical Inc (AVNS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Avanos Medical Inc (AVNS) has an earnings forecast score of 6.00, placing it 172nd in its industry, with an average analyst price target of $14.00. One analyst currently rates the stock as "Hold". The company's expected revenue for the next quarter is $173.00 million, and its EPS is projected to be $0.16.
Avanos Medical Inc (AVNS) Financial Health: Profitability & Balance Sheet Analysis
Avanos Medical Inc (AVNS) has a strong financial health score of 7.17, ranking 104 out of 204 in its industry. The company demonstrated robust operating efficiency with a year-over-year revenue increase of 8.78% to $182.20M and a net profit increase of 22.73%. This analysis highlights the company's positive financial performance and solid standing within the Healthcare Equipment & Supplies sector.
Avanos Medical Inc (AVNS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of Avanos Medical Inc (AVNS) shareholder structure, listing major shareholders and their respective proportions, as well as institutional holdings over several quarters. It also categorizes shareholders by type and shows changes in holdings for key institutional investors. The data includes share percentages, number of institutions, shares held, and corresponding changes, alongside related ETF allocations.
AIP agrees $1.27bn takeover of Avanos Medical in major medtech buyout
American Industrial Partners (AIP) has agreed to acquire medical technology company Avanos Medical for approximately $1.272 billion in an all-cash transaction, offering shareholders $25 per share. The deal, which represents a 72.1 percent premium to Avanos's recent closing price, will make Avanos a privately held company and delist its stock from the NYSE. This acquisition highlights continued private equity interest in the medtech sector and is expected to enhance Avanos's innovation and market position.
A Look At Avanos Medical (AVNS) Valuation After Its Recent Share Price Surge
Avanos Medical (AVNS) has seen a significant share price surge of 87% in the last 3 months and 124% year-to-date, despite a 37.38% decline over the past five years and the company still reporting a net loss. The company's Price-to-Sales (P/S) ratio of 1.6x is below industry peers but higher than Simply Wall St's estimated fair P/S of 1.1x, suggesting the market is willing to pay a premium for future growth for the medical technology company. Investors are advised to assess the company's financials carefully given its loss-making status and potential risks.
Avanos Medical stock (US05350V1061): medtech specialist seeks momentum after strategic refocus
Avanos Medical (AVNS) is currently trading around $25 with a market capitalization of $1.2 billion, following a strategic refocus on pain management and single-use medical devices. The company differentiates itself through clinically differentiated products and optimizing its portfolio after previous divestitures. Its success hinges on sustainable growth, margin stability, and effectively navigating the competitive medtech landscape, especially in areas like pain management, digestive health, and infection prevention.
(AVNS) as a Liquidity Pulse for Institutional Tactics
This article analyzes Avanos Medical Inc. (NASDAQ: AVNS) using AI models to provide institutional trading strategies. It highlights a strong near-term sentiment, neutral mid-term outlook, and positive long-term bias, noting no resistance levels above the current price. The analysis offers specific strategies for position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Avanos Medical stock hits 52-week high at 25.18 USD By Investing.com
Avanos Medical (AVNS) stock has hit a new 52-week high of $25.18, with shares trading at $25.11, demonstrating a remarkable 97% total return over the past year. The company's market capitalization is now $1.16 billion, reflecting strong investor confidence. Additionally, Avanos Medical is set to be acquired by American Industrial Partners for approximately $1.27 billion, with stockholders receiving $25.00 per share in cash.
Avanos Medical stock hits 52-week high at 25.18 USD By Investing.com
Avanos Medical stock has reached a 52-week high of $25.18, trading at $25.11, demonstrating a 97% total return over the past year. This milestone follows the announcement of its acquisition by American Industrial Partners for approximately $1.27 billion, with stockholders receiving $25.00 per share, a 72.1% premium. Analysts expect net income growth and profitability for the company this year.
Avanos Medical stock hits 52-week high at 25.18 USD By Investing.com
Avanos Medical Inc. (AVNS) recently hit a 52-week high of $25.18, with shares trading at $25.11, reflecting a 97% total return over the past year. Despite this surge, InvestingPro suggests the stock remains undervalued relative to its Fair Value, anticipating net income growth and future profitability. Additionally, the company announced an acquisition by American Industrial Partners for approximately $1.27 billion, with stockholders receiving $25.00 per share, and an increase in CEO David C. Pacitti’s long-term incentive grant target value to $5.5 million starting in 2026.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of
Brodsky & Smith is investigating potential breaches of fiduciary duties by the Boards of Directors of Avanos Medical, Global Business Travel Group, LiveRamp Holdings, and Equity Residential in connection with their respective merger agreements. The law firm is inviting shareholders to contact them to discuss the investigations, focusing on whether the transactions offer fair value to shareholders. Brodsky & Smith specializes in representing shareholders in securities and class action lawsuits.
Avanos Medical stock hits 52-week high at 25.18 USD By Investing.com
Avanos Medical (AVNS) recently hit a 52-week high of $25.18, with shares trading at $25.11, marking a significant 97% total return over the past year. InvestingPro analysis suggests the stock remains undervalued despite its strong rally, with net income expected to grow this year. The company is also set to be acquired by American Industrial Partners for approximately $1.27 billion, with stockholders receiving $25.00 per share in cash.
Avanos Medical (NYSE: AVNS) to be acquired for $25.00 per share by AIP‑backed buyer
Avanos Medical (NYSE: AVNS) has agreed to be acquired by an AIP-affiliated entity for $25.00 per share in cash. The all-cash merger, valued at approximately $1.42 billion, is expected to close in the second half of 2026, pending stockholder and regulatory approvals. The Board of Directors unanimously recommends the acquisition, citing the attractive premium and liquidity for shareholders.
A Look At Avanos Medical (AVNS) Valuation After Its Recent Share Price Surge
Avanos Medical (AVNS) has seen a significant share price surge of 72.35% in the past three months and 121.38% year-to-date, contrasting with more modest long-term returns. Despite reporting a loss of US$74.4 million, the stock trades at a Price-to-Sales (P/S) ratio of 1.6x, which is lower than the industry average but above its estimated fair P/S of 1.2x. This suggests the market is valuing Avanos Medical at a discount to sector benchmarks, though still at a premium to its fair value model, amidst strong recent momentum.
(AVNS) Risk Channels and Responsive Allocation
This article provides an AI-driven analysis of Avanos Medical Inc. (NASDAQ: AVNS), identifying a neutral near and mid-term outlook with a long-term positive bias but elevated downside risk. It offers specific trading strategies—Long Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors. The report details support and resistance levels across different time horizons, generated by AI models for optimal risk management.
Top 2 Health Care Stocks That May Plunge This Month
Two health care stocks, Avanos Medical Inc (AVNS) and Agilon Health Inc (AGL), are identified as potentially overbought based on their high Relative Strength Index (RSI) values. Both companies recently reported strong financial results and significant stock price gains, but their high RSI suggests they might be due for a correction. Investors are cautioned to consider momentum when making trading decisions for these stocks.
Avanos Medical (NYSE:AVNS) - Aandelenanalyse
This report provides a detailed analysis of Avanos Medical (NYSE:AVNS), a medical technology company. It covers valuation metrics, future growth prospects, past performance, financial health, dividend information, management, and ownership. The analysis highlights recent news, including an acquisition offer from American Industrial Partners and various quarterly earnings reports, while also pointing out risks such as volatile share price and declining earnings.
Avanos Medical (NYSE: AVNS) director awarded 12,003 cash-settled RSUs
Avanos Medical director Indrani Lall Franchini was granted 12,003 cash-settled Restricted Share Units (RSUs) on May 8, 2026, replacing a prior grant from January 2, 2025. These RSUs represent a contingent right to receive a cash payment equal to the value of one share of Avanos common stock and will vest upon the termination of her service on the company's Board of Directors. The grant aims to align her incentives with her continued board tenure.
Avanos Medical (AVNS) director awarded 12,003 cash-settled restricted share units
Avanos Medical director Patrick J. O’Leary was granted 12,003 cash-settled restricted share units on May 8, 2026, as compensation. These units, which replace an earlier grant from January 2, 2025, represent a contingent right to a cash payment equivalent to the value of one share of Avanos common stock and will vest upon the termination of O’Leary's service on the company's Board of Directors. This compensation structure aims to align his incentives with the company's long-term performance and board service.
Avanos Medical (NYSE: AVNS) director awarded 12,003 cash-settled restricted units
Avanos Medical (AVNS) director Lisa Egbuonu-Davis was granted 12,003 cash-settled restricted share units on May 8, 2026. These units replace a previous grant and will vest upon her termination of service from the company's Board of Directors. The Form 4 filing indicates a compensation-related grant, not an open-market transaction of shares.
Avanos Medical (AVNS) director awarded 12,003 cash-settled RSUs
Avanos Medical director Gary Blackford was granted 12,003 cash-settled Restricted Share Units (RSUs) on May 8, 2026. These RSUs replace an earlier grant from January 2, 2025 and will vest upon his termination of service from the company's Board of Directors. Each RSU represents a contingent right to a cash payment equal to the value of one share of Avanos common stock, aligning his incentives with the company's performance.
A Look At Avanos Medical (AVNS) Valuation After Sharp Recent Share Price Gains
Avanos Medical (AVNS) has seen a significant surge in its share price recently, with an 80.94% increase in one month and 121.56% year-to-date, despite a 36.03% loss over five years. The company, currently valued at US$1.16 billion with US$715.9 million in revenue and a US$74.4 million net loss, trades at a Price-to-Sales (P/S) ratio of 1.6x. While this is lower than industry averages, it appears slightly richer than its estimated fair P/S of 1.2x, suggesting potential for valuation adjustment if market sentiment shifts.
(AVNS) Movement as an Input in Quant Signal Sets
This article analyzes Avanos Medical Inc. (NASDAQ: AVNS) using AI models, identifying neutral near and mid-term readings that could moderate a long-term positive bias. It provides specific institutional trading strategies, including long, momentum breakout, and risk hedging, along with multi-timeframe signal analysis indicating support and resistance levels. The report highlights elevated downside risk due to a lack of additional long-term support signals.
A Look At Avanos Medical (AVNS) Valuation After Sharp Recent Share Price Gains
Avanos Medical (AVNS) has seen significant recent share price gains of 80.94% in one month and 121.56% year-to-date, despite a 36.03% loss over five years. The company, valued at US$1.16 billion with US$715.9 million in revenue and a US$74.4 million net loss, trades at a Price-to-Sales (P/S) ratio of 1.6x. While this is below industry averages, it's considered "about right" but richer than its estimated fair P/S of 1.2x, suggesting potential for valuation adjustment if sentiment shifts.
Avanos Medical stock hits 52-week high at 24.76 USD
Avanos Medical Inc. (AVNS) stock reached a 52-week high of $24.76 USD, reflecting a 96.82% 1-year change and nearly 120% year-to-date returns. The company is set to be acquired by American Industrial Partners for approximately $1.272 billion, with stockholders receiving $25.00 per share. InvestingPro analysis indicates the stock is undervalued relative to its Fair Value and has a "GOOD" financial health score.
Avanos Medical stock hits 52-week high at 24.76 USD By Investing.com
Avanos Medical (AVNS) stock reached a 52-week high of $24.76, demonstrating a strong performance with a 96.82% 1-year change and nearly 120% year-to-date returns. The company's market capitalization stands at $1.16 billion, trading significantly above its 52-week low. This surge is attributed to strategic initiatives, operational efficiencies, and a broader rally in the healthcare sector, with InvestingPro analysis suggesting the stock remains undervalued relative to its Fair Value.
Avanos Medical (AVNS) Trailing EPS Loss Of US$1.57 Challenges Bullish Community Narratives
Avanos Medical (AVNS) reported a trailing twelve-month basic EPS loss of US$1.57 and a net loss of US$72.9 million on US$701.2 million in revenue, leading to challenges against bullish narratives. The company's profitability has weakened over the past five years, with losses increasing despite quarterly revenues generally staying between US$167.5 million and US$180.9 million. While the stock trades at a lower P/S ratio compared to the industry and has a 17% discount to its DCF fair value, significant questions remain regarding earnings quality and operational stability due to inconsistent profits.
[10-Q] AVANOS MEDICAL, INC. Quarterly Earnings Report
Avanos Medical, Inc. (AVNS) released its first-quarter 2026 earnings report, showing a rise in net sales to $182.2 million from $167.5 million, primarily driven by its Specialty Nutrition Systems segment. Despite the revenue growth, net income decreased to $5.1 million from $6.6 million. The report also highlights a pending cash merger where affiliates of American Industrial Partners will acquire Avanos for $25.00 per share, which, upon completion, will result in the company's delisting from the NYSE.
Avanos Medical earnings ahead as private equity deal looms
Avanos Medical Inc. is set to report its first-quarter earnings, potentially one of its last as a public company, amid a pending $1.3 billion acquisition by American Industrial Partners. Analysts forecast earnings of $0.24 per share on $169 million in revenue, a sequential dip but a year-over-year improvement. Investors will be watching for updates on full-year guidance, sequential performance, and the acquisition timeline given the deal is expected to close in the second half of 2026.
Avanos Medical (AVNS) posts Q1 2026 results and $1.272B AIP buyout deal
Avanos Medical (AVNS) reported its Q1 2026 financial results, including net sales of $182.2 million, an increase of 8.8% year-over-year, largely driven by its Specialty Nutrition Systems segment. Despite revenue growth, net income decreased to $5.1 million from $6.6 million in the prior year, and the company experienced a significant shift from positive to negative free cash flow. The report also highlighted the pending all-cash acquisition of Avanos Medical by affiliates of American Industrial Partners for an enterprise value of $1.272 billion.
Avanos Medical (AVNS) Trailing EPS Loss Of US$1.57 Challenges Bullish Community Narratives
Avanos Medical (AVNS) reported a Q1 2026 basic EPS loss of US$1.57 and a net loss of US$72.9 million for the trailing twelve months, despite revenues ranging from US$167.5 million to US$180.9 million per quarter. The company's profitability has worsened over five years, with critics noting persistent losses and volatile earnings. Despite trading at a P/S of 1.6x—below industry averages and its DCF fair value—the continued losses and high share price volatility concern investors.
